Facilitating Adoptive Cell Therapy Clinical Trials
Initial successes of adoptive cell therapies for the treatment of hematological malignancies are driving the development of many more cell-based therapies and, consequently, increasing the advancement of product candidates into the solid tumor setting.
“The cell and gene therapy ecosystem is complex, so all stakeholders must learn from one another to continue to refine processes.”1
DESCRIPTION:
In this Applied Clinical Trials article, “Facilitating Adoptive Cell Therapy Clinical Trials,” learn about the current challenges in adoptive cell therapy clinical development from both the site and CRO perspective and gain insights into evolving approaches to improve the patient experience and bring these transformative therapies to more patients.
authors:
Fiona Thistlethwaite, MB, BChir, PhD MRCP
Medical Oncology Consultant, Experimental Cancer Team
The Christie NHS Foundation Trust
Honorary Professor, University of Manchester
Panteli Theocharous, FIBMS, PhD, FRCPATH
Global Vice President
Cell and Gene Therapy Strategy Lead
PPD Biotech
PPD has an integrated and comprehensive end-to-end process to help you advance your adoptive cell therapy development program, informed by over a decade of work in managing these highly specialized clinical trials. In this pioneering development space, PPD can help you better predict how patients, caregivers, sites, regulators and payers will react to your therapy.